Meta Information
ID:ss-31
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
SS-31 is cleared from the body by the kidneys. Impaired kidney function can cause the peptide to accumulate to potentially toxic levels, increasing the risk of adverse effects.
Actionable advice:
Use only under strict medical supervision with potential dose adjustments if you have any degree of kidney disease.
Target id:
/class/nephrotoxic-agents
Target name:
Nephrotoxic Agents (NSAIDs, ACEi, ARBs)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Concurrent use of SS-31 with other drugs known to be potentially harmful to the kidneys (like high-dose NSAIDs or certain antibiotics) can compound the risk of renal injury.
Actionable advice:
Avoid using other kidney-toxic drugs simultaneously unless medically necessary and closely monitored by a physician.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The safety of SS-31 during human pregnancy has not been established. The potential risks to a developing fetus are unknown.
Actionable advice:
Avoid completely if you are pregnant or planning to become pregnant.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if SS-31 passes into breast milk or what its effects might be on a nursing infant.
Actionable advice:
Avoid completely while breastfeeding.
Target id:
/biomarker/advanced-renal-function-panel
Target name:
Advanced Renal Function Panel (eGFR, Creatinine, Cystatin C)
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Due to its renal clearance pathway, regular monitoring of kidney function is a critical safety requirement to ensure the drug is being cleared properly and not accumulating.
Actionable advice:
Obtain baseline and periodic kidney function tests (e.g., eGFR, creatinine) before and during SS-31 therapy.
Target id:
/dietary/alcohol-acute
Target name:
Alcohol
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Alcohol is a known mitochondrial toxin that increases oxidative stress and impairs mitochondrial function, which may directly counteract the therapeutic goals of SS-31.
Actionable advice:
Strictly limit or avoid alcohol consumption to ensure the maximal benefit of SS-31 therapy.
Target id:
/intervention/coenzyme-q10
Target name:
Coenzyme Q10 (CoQ10)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
CoQ10 is an essential component of the electron transport chain for ATP production. Its role may complement SS-31's action of stabilizing the mitochondrial membrane where this process occurs.
Actionable advice:
Consider taking concurrently, as it may provide additive support for mitochondrial energy production.
Target id:
/intervention/l-carnitine
Target name:
L-Carnitine
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
L-Carnitine facilitates the transport of fatty acids into the mitochondria for beta-oxidation. This may synergize with SS-31 by providing fuel for the energy production machinery that SS-31 helps to stabilize.
Actionable advice:
Consider taking concurrently for potentially enhanced support of mitochondrial metabolism.
Target id:
/intervention/alpha-lipoic-acid
Target name:
Alpha-Lipoic Acid (ALA)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
ALA is a potent mitochondrial antioxidant. This action may complement SS-31's ability to reduce mitochondrial reactive oxygen species (ROS) production, offering dual protection against oxidative stress.
Actionable advice:
Consider taking concurrently to potentially enhance mitochondrial antioxidant defenses.
Target id:
/circadian/wake
Target name:
Waking Up
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
null
Hours after target:
1
Description:
Mitochondrial activity follows a circadian rhythm, with higher energy demands in the morning. Administering SS-31 upon waking may align its effects with the body's natural metabolic cycle.
Actionable advice:
Administer in the morning, within an hour of waking, for potential alignment with circadian bioenergetics.
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
As SS-31 is administered by subcutaneous injection, there is a theoretical increased risk of bruising or hematoma formation at the injection site in individuals taking blood-thinning medications.
Actionable advice:
Exercise caution and monitor injection sites for excessive bruising if you are taking anticoagulant or antiplatelet drugs.